

Curriculum vitae

Personal Data

Title	Professor Dr
First name	Eva
Surname	Hoch
Current institution(s)/location(s), country	IFT Institut für Therapieforschung Centre for Mental Health and Addiction Research Leopoldstrasse 175 80804 Munich, Germany Department of Clinical Psychology and Psychotherapy Charlotte Fresenius University Infanteriestr. 11a 80797 Munich, Germany Clinic of Psychiatry and Psychotherapy Ludwig-Maximilian University Nussbaumstr. 7 80336 Munich, Germany

Qualification and career

Since 10/2023	Professor of Clinical Psychology and Psychotherapy, Charlotte Fresenius University, Munich
Since 1/2022	Scientific director, IFT Institute for Therapy Research, Centre for Mental Health and Addiction Research, Munich
01/2021	Brandenburg Medical School, Neuruppin, awarded a W3 professorship in Clinical Psychology and Psychotherapy, rejected the offer
4/2019	Ludwig-Maximilians-University Munich Habilitation in the subject "Clinical Psychology and Neuropsychology"
11/2018	Certified supervisor, Centre for Interdisciplinary Psychotherapy CIP, Munich
4/2017	Heidelberg University, Mannheim Medical Faculty, Habilitation in the subject "Clinical Psychology, Neuropsychology and Medical Psychology"
Since 2015	Clinic of Psychotherapy and Psychotherapy, Ludwig-Maximilian University, Munich
2012	Karl-Eberharts University, Tübingen Baden-Württemberg certificate for university didactics in medicine
2010-2015	Centre for Mental Health, Mannheim, Department of Medical Psychology, Ruprecht Karls University, Mannheim (2010-2017)
2010	Approbation in Psychotherapy

2005	PhD in Psychology, Faculty of Mathematics and Natural Sciences at TU Dresden (summa cum laude)
2004-2010	Institute for Clinical Psychology and Psychotherapy, TU Dresden
2001-2004	Max-Planck-Institute of Psychiatry (guest researcher) and Institute for Clinical Psychology and Psychotherapy, TU Dresden
1998-2001	IFT Institut für Therapieforschung, German Centre for Drugs and Drug Addiction
1991-1997	Phillips University of Marburg Diploma in psychology (grade: 1.1)
1990-1991	Au-pair in Paris (France)
1990	Abitur am Dietrich-Bonhoeffer Gymnasium, Metzingen (BW)

Commitment to the science system

- Consultant to World Health Organization (WHO)
- Consultant to European Drugs Agency (EUDA)
- Consultant to World Antidoping Agency (WADA)
- President of the German Society for Addiction Research and Therapy (DG-Sucht)
- President of the German Addiction Congress 2023,
- Member of the Federal Government's Expert Council on New Psychoactive Substances
- Member of the German Society for Psychology (DGP) / Clinical Psychology Section,
- Member of the German Society for Psychiatry, Psychotherapy, Psychosomatics and Neurology (DGPPN),
- Member of the Bavarian Academy for Addiction Issues (BAS)
- Since 2010 participation in the development of AWMF guidelines (alcohol, tobacco, medication, cannabis, internet) Since 2001: Academic teaching, examination work and supervision of students at the TU Dresden, the ZI Mannheim and the LMU Munich (psychological and medical faculties)⁴

Supporting researchers in early career phases

Since 2023: Supervision of dissertations, master's and bachelor's theses (CFH)

Since 2015: Supervision of dissertations, master's and bachelor's theses (LMU)

2010-2015: Supervision of dissertations (ZI Mannheim)

2009: Founder of the Young Investigators Group of the German Society for Addiction Research and Addiction Therapy

2003-2010: Supervision of dissertations and diploma theses (TU Dresden)

Recognition by the science system

2023: President of German Society for Addiction Research and Therapy

2023: President of 15. German Addiction Congress

2017: Wilhelm Feuerlein Prize from the German Addiction Foundation

2017: EMCDDA Shortlist Scientific Paper Award

2010: Research Prize of the German Society for Behavioral Therapy

2006: Werner Straub Prize for outstanding achievements in science Qualification (TU Dresden)

2006: Young Talent Award from the German Society for Addiction Research

2005: Travel grant from the German Research Foundation

Motivation

As a scientist, it is important to me to educate society about mental health. The focus of my research are cannabinoids. Recently, I have been looking at the different forms of cannabis legalization and the many different effects on society. With high-quality data, I want to help ensure that the public discussion about the risks and benefits of cannabinoids is fact-based and not driven by emotions or worldviews. Improving the care of people with addictions has driven me for 25 years. My work is embedded in a large international network of researchers. With my expertise, I advise the WHO, the European Drug Monitoring Center, the World Doping Agency, the German Federal Government and others.

References

- Holst M, Nowak D, Hoch E. Cannabidiol As a Treatment for COVID-19 Symptoms? A Critical review. *Cannabis Cannabinoid Res.* 2022 Jul 26. doi :10.1089/can.2021.0135. Epub ahead of print. PMID: 35881839.
- Connor JP, Stjepanović D, Le Foll B, Hoch E, Budney AJ, Hall WD. Cannabis use and cannabis use disorder. *Nat Rev Dis Primers.* 2021 Feb 25;7(1):16. doi :10.1038/s41572-021-00247-4. PMID: 33627670; PMCID: PMC8655458.
- Preuss UW, Huestis MA, Schneider M, Hermann D, Lutz B, Hasan A, Kambeitz J, Wong JWM, Hoch E. Cannabis Use and Car Crashes: A Review. *Frontline Psychiatry.* 2021 May 28;12:643315 . doi : 10.3389/fpsy.2021.643315. PMID: 34122176; PMCID: PMC8195290.
- Lees R, Hines LA, D'Souza DC, Stothart G, Di Forti M, Hoch E, Freeman TP. Psychosocial and pharmacological treatments for cannabis use disorder and mental Health comorbidities: a narrative review. *Psychol Med.* 2021 Feb;51(3):353-364. doi : 10.1017/S0033291720005449. Epub 2021 Feb 4. PMID: 33536109.
- Hoch E, Lorenzetti V. Mapping and mitigating the health risks of legalizing recreational cannabis use: a call for synergy between research and policy. *World Psychiatry.* 2020 Jun;19(2):189-191. doi : 10.1002/wps.20738. PMID: 32394580; PMCID: PMC7214955.
- Lorenzetti V, Hoch E, Hall W. Adolescent cannabis use, cognition, brain health and educational outcomes: A review of the evidence. *EurNeuropsychopharmacol .* 2020 Jul;36:169 -180. doi : 10.1016/j.euroneuro.2020.03.012. Epub 2020 Apr 5. PMID: 32268974.
- Hasan, A., von Keller, R., Friemel, CM, Hall, W., Schneider, M., Koethe, D., Leweke., FM, Strube, W., & Hoch, E. (2020). Cannabis use and psychosis: a review of reviews. *European archives of psychiatry and clinical neuroscience*, 270(4), 403–412. <https://doi.org/10.1007/s00406-019-01068-z>
- Hoch E, Preuss UW. Cannabis, cannabinoids and cannabis use disorders [Cannabis, Cannabinoids and Cannabis Use Disorders]. *Progress Neurol Psychiatrist.* 2019 Dec;87(12):714-728. German. doi : 10.1055/a-1008-7427. Epub 2019 Dec 17.

Hoch, E., Niemann, D., von Keller, R., Schneider, M., Friemel, C. M., Preuss, U. W., Hasan, A., & Pogarell, O. (2019). How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. *European Archives of Psychiatry and Clinical Neuroscience*, 269(1), 87–105. [IF 5.28]

Hoch, E., Friemel, C.M. & Schneider, M. (2018). *Cannabis: Potenzial und Risiko. Eine wissenschaftliche Bestandsaufnahme*. Heidelberg: Springer Verlag.

Hoch, E, Bonnet, U., Havemann-Reinecke, U., Ganzer, F., Thomasius, R & Preuss, U.W. (2015). Risks associated with the non-medicinal use of cannabis. *Deutsches Ärzteblatt International*, 112: 271–8. [IF: 8.251]

Hoch, E., Mühlig, S., Höfler, M., Lieb, R. & Wittchen H.-U. (2004). How prevalent is smoking and nicotine dependence in primary care? *Addiction*, 99, 1586–1598. [IF: 7.256]